Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Dostarlimab (Jemperli, GlaxoSmithKline) is indicated 'in combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy'.

The dosage schedule is available in the summary of product characteristics for dostarlimab.

The list price for dostarlimab is £5,887.33 per 500‑mg vial (excluding VAT, BNF online, accessed March 2025).

The company has a commercial arrangement. This makes dostarlimab available to the NHS with a discount. The size of the discount is commercial in confidence.